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Background: The increasing trend of antibiotic resistance requires effective second-line Helicobacter pylori (H. pylori)
treatment in high prevalence area of H. pylori. The aim of our study was to evaluate the reinfection rate of H. pylori
after second-line treatment that would determine the long-term follow up effect of the rescue therapy.
Methods: A total of 648 patients who had failed previous H. pylori eradication on standard triple therapy were
randomized into two regimens: 1, esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d),
metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d) (EBMT) or 2, moxifloxacin (400 mg q.d.), esomeprazole
(20 mg b.i.d), and amoxicillin (1000 mg b.i.d.) (MEA). At four weeks after completion of eradication therapy, H. pylori
tests were performed with 13C urea breath test or invasive tests. In patients who maintained continuous H. pylori
negativity for the first year after eradication therapy, H. pylori status was assessed every year. For the evaluation
of risk factors of reinfection, gender, age, clinical diagnosis, histological atrophic gastritis or intestinal metaplasia
were analyzed.
Results: The recrudescence rate of the EBMT was 1.7% and of the MEA group 3.3% (p = 0.67). The annual reinfection
rate of H. pylori of EBMT was found to be 4.45% and the MEA group 6.46%. Univariate analysis (Log-rank test) showed
no association with any clinical risk factor for reinfection.
Conclusions: The long-term reinfection rate of H. pylori stayed low in both of bismuth-containing quadruple therapy
and moxifloxacin-based triple therapy; thus reinfection cannot affect the choice of second-line treatment.
Trial registration: Clinical Trial Registration Number NCT01792700
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Helicobacter pylori (H. pylori) is a common pathogen of
the gastric mucosa. It is estimated that at least 50% of
the world’s human population has H. pylori infection [1].
Since the majority of patients with H. pylori infection do
not have any related clinical disease, routine screening is* Correspondence: nayoungkim49@empas.com
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reproduction in any medium, provided the ornot considered [2]. However, as the current evidence
suggests that H. pylori play a major role in peptic ulcer
disease, gastric MALT lymphoma and in gastric cancer [3],
screening and treatment in these diseases are recom-
mended in several guidelines [2,4-7]. In addition, European
guidelines recommend eradicating H. pylori infection in
first-degree relatives of patients with gastric cancer, in long
term NSAIDS or acid suppression users and in patients
with functional dyspepsia [4]. According to these guide-
lines, public health efforts toward eradication will be more
effective in H. pylori high prevalence areas. Naturally,
it is expected that increasing use of antibiotics must lead. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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commonly used initial treatment is a triple regimen com-
bining a proton pump inhibitor (PPI) with two antibiotics
(clarithromycin and amoxicillin/or metronidazole) for
the eradication of H. pylori [2,4-7]. Although this regi-
men has been shown to be effective in numerous clinical
trials, the most recent data show that the eradication rate
has declined to less than 80% worldwide, largely related
to development of resistance to clarithromycin [8]. In
Korea, the recent eradication rate of this regimen was
less than 80% in a long-term follow up study (≥ 5 years)
[9,10]. Therefore, this decreasing eradication rate re-
quires effective second-line treatment. Many clinicians
have been using second-line therapy with bismuth-
containing quadruple therapy or including fluoroquino-
lone antibiotics such as levofloxacin and moxifloxacin.Figure 1 Schematic study flow chart.In this situation, reinfection of H. pylori will determine
the long-term effect of the eradication therapy for H. pyl-
ori. If a regimen shows a high reinfection rate, then this
eradication therapy should be avoided or strictly used
only when absolutely indicated for H. pylori eradication.
We reported the long-term annual reinfection rate of
H. pylori in standard PPI-based triple therapy to be
3.51% per year in Korea [11]. Now that second-line
therapy is frequently used there is increasing interest
regarding the reinfection and recrudescence rates after
rescue therapy. However, there are few reports regard-
ing the reinfection rate of H. pylori after quadruple
therapy [12] and none for quinolone based triple therapy.
From this background the aim of our study was to evalu-
ate the reinfection rate of H. pylori after two kinds of
second-line treatment over a long-term follow up period.
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tion after this second-line treatment.
Methods
Study population
The schematic flow of this study is shown in Figure 1.
This was a prospective study performed between 2003
and 2010 at Seoul National University Bundang Hospital
in Korea. A total of 648 patients with persistent H. pylori
infection after first-line treatment (PPI-based triple
therapy) were enrolled. PPI-based triple therapy included
PPI (standard dose), amoxicillin 1 g, and clarithromycin
500 mg, all twice daily, for 7 days. Patients were consid-
ered persistent H. pylori infection if 13C-urea breath test
(UBT) or invasive H. pylori test (Giemsa histology, CLO
test, culture) were positive despite PPI-based triple ther-
apy. Patients were excluded from the study if they had a
history of renal or hepatic impairment, previous gastric
surgery, pregnancy or lactation, therapy with steroids or
non-steroidal anti-inflammatory drugs, or therapy with
a proton pump inhibitor (PPI) or antibiotics within four
weeks of entry. Between 2003 and 2006, the 44 patients
with persistent H. pylori infection were treated with
bismuth-containing quadruple therapy. Between 2007
and 2010, 604 patients with persistent H. pylori infection
were randomized into two kinds of second-line therapy
(bismuth-containing quadruple therapy or moxifloxacin-Table 1 Baseline demographic and clinical characteristics of su
therapy (EBMT) or moxifloxacin-based triple therapy (MEA)
Variable category Total
(N = 175)
Gender (N = 175)
Male (104, 59.4%)
Female (71, 40.6%)
Age (years) (mean ± SD) (N = 175)
(56.6 ± 9.4)
Clinical diagnosis (N = 175)
Early gastric cancer (40, 22.9%)
Dysplasia (19, 10.9%)
Peptic ulcer disease (34, 19.4%)
Chronic gastritis (82, 46.9%)
Histological AG in either antrum or body (N = 116)
Yes (67, 57.8%)
No (49, 42.2%)
Histological IM in either antrum or body (N = 144)
Yes (84, 58.3%)
No (60, 41.7%)
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d),
(400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atro
All of early gastric cancer patients were cured by endoscopic submucosal dissection
*p-value for Pearson chi-square test for comparison of categorical data, and indepebased triple therapy). However, if the patient preferred
one regimen, after sufficient information for side effect
and eradication rate of each regimen a change was per-
mitted. Finally, 222 patients were treated for 14 days
with esomeprazole 20 mg b.i.d, tripotassium dicitrate
bismuthate 300 mg q.i.d, metronidazole 500 mg t.i.d,
and tetracycline 500 mg q.i.d (EBMT) as second-line
treatment regimen for H. pylori infection. 426 patients
were treated for 14 days with moxifloxacin 400 mg q.d,
esomeprazole 20 mg b.i.d, and amoxicillin 1000 mg b.i.d
(MEA) as second-line treatment regimen for H. pylori
infection. At four weeks after completion of the second-
line treatment, H. pylori eradication was evaluated by
13C-UBT or invasive tests. Invasive tests were per-
formed in the patients in whom follow up endoscopic
examination was necessary for peptic ulcer, adenoma or
gastric cancer. H. pylori negative status after eradication
was defined as a negative 13C-UBT or all negative of
Giemsa stain, CLO test, and culture. Among 222 pa-
tients with EBMT eradication therapy and 426 patients
with MEA eradication therapy, 169 patients and 308 pa-
tients were found to be in eradicated status, respectively
(Figure 1).
All subjects provided informed consent, and the study
protocol was approved by the Ethical Committee at Seoul
National University Bundang Hospital. ClinicalTrials.gov
registration number is NCT01792700.bjects who maintained the eradicated state by quadruple
EBMT MEA p-value*
(N = 59) (N = 116)
(n = 59) (n = 116)
(35, 59.3%) (69, 59.5%) 0.98
(24, 40.7%) (47, 40.5%)
(n = 59) (n = 116) 0.67
(56.1 ± 9.3) (56.8 ± 9.5)
(n = 59) (n = 116)
(11, 18.6%) (29, 25.0%) 0.06
(3, 5.1%) (16, 13.8%)
(17, 28.8%) (17, 14.7%)
(28, 47.5%) (54, 46.6%)
(n = 37) (n = 79)
(21, 56.8%) (46, 68.7%) 0.88
(16, 43.2%) (33, 41.8%)
(n = 47) (n = 97)
(23, 48.9%) (61, 62.9%) 0.11
(24, 51.1%) (36, 37.1%)
metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin
phic gastritis, IM, intestinal metaplasia.
.
ndent samples t-test for comparison of age.
Kim et al. BMC Gastroenterology 2013, 13:138 Page 4 of 9
http://www.biomedcentral.com/1471-230X/13/138Invasive Helicobacter pylori test (Giemsa histology,
CLO test, and culture) and histology
To determine the presence of current H. pylori infection,
10 biopsy specimens were taken from the gastric mucosa
at each endoscopy (two biopsy specimens each from the
greater curvature of the antrum and body, and three
each from the lesser curvature of the antrum and body).
Among them, four biopsy specimens (one each from the
greater curvature and lesser curvature of the antrum
and body) were fixed in formalin, and used for determin-
ation of H. pylori infection by Giemsa staining. Another
four specimens from the four gastric mucosa areas men-
tioned above were used for H. pylori culturing. The
remaining two specimens from the lesser curvature of
the antrum and body were used for the rapid urease test










Gender (N = 59) (n = 7) (n = 52)
Male (35, 59.3%) (4, 57.1%) (31, 59.6%)
Female (24, 40.7%) (3, 42.9%) (21, 40.4%)
Age (mean ± SD) (N = 59) (n = 7) (n = 52)
(56.1 ± 9.3) (59.9 ± 9.8) (55.6 ± 9.2)
20-29 (1, 1.7%) (0, 0.0%) (1, 1.9%)
30-39 (1, 1.7%) (0, 0.0%) (1, 1.9%)
40-49 (13, 22.0%) (2, 22.2%) (11, 21.2%)
50-59 (21, 35.6%) (1, 14.3%) (20, 38.5%)
60-69 (20, 33.9%) (3, 42.9%) (17, 32.7%)
70-79 (3, 5.1%) (1, 14.3%) (2, 3.8%)
80-89 (0, 0.0%) (0, 0.0%) (0, 0.0%)
Clinical diagnosis (N = 59) (n = 7) (n = 52)
Early gastric cancer (11, 18.6%) (0, 0.0%) (11, 21.2%)
Dysplasia (3, 5.1%) (1, 14.3%) (2, 3.8%)
Peptic ulcer disease (17, 28.8%) (4, 57.1%) (13, 25.0%)
Chronic gastritis (28, 47.5%) (2, 28.6%) (26, 50.0%)
Histological AG in either
antrum or body
(N = 37) (n =6) (n = 31)
Yes (21, 56.8%) (5, 83.3%) (16, 51.6%)
No (16, 43.2%) (1, 16.7%) (15, 48.4%)
Histological IM in either
antrum or body
(N = 47) (n = 6) (n = 41)
Yes (23, 48.9%) (4, 66.7%) (21, 51.2%)
No (24, 51.1%) (2, 33.3%) (20, 48.8%)
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d),
(400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atro
All of early gastric cancer patients were cured by endoscopic submucosal dissection
* P-value for Log-rank test.Four of the biopsy specimens used for determination of
H. pylori infection were also used for histological evalu-
ation. These specimens were examined for the presence of
gastric atrophy and intestinal metaplasia by H&E staining.
The presence of atrophy on any of four specimens was di-
agnosed as gastric atrophy, and the same method was ap-
plied to intestinal metaplasia. The definition of atrophy is
the loss of appropriate glands including both metaplastic
and non-metaplastic atrophy. Both metaplastic and non-
metaplastic atrophy can be allocated to one of three grades
of severity using grading criteria modeled on those sug-
gested by the original and the updated Sydney System [13].
13C-urea breath test
Patients fasted for 4 h before testing. Then, 100 mg











(N = 116) (n = 19) (n = 97)
0.816 (69, 59.5%) (12, 63.2%) (57, 58.8%) 0.353
(47, 40.5%) (7, 36.8%) (40, 41.2%)
(N = 116) (n = 19) (n = 97)
(56.8 ± 9.5) (56.7 ± 9.4) (56.8 ± 9.6)
0.306 (1, 0.9%) (0, 0.0%) (1, 1.0%) 0.479
(3, 2.6%) (0, 0.0%) (3, 3.1%)
(21, 18.1%) (6, 31.6%) (15, 15.5%)
(40, 34.5%) (5, 26.3%) (35, 36.1%)
(42, 36.2%) (6, 31.6%) (36, 37.1%)
(8, 10.5%) (2, 10.5%) (6, 6.2%)
(1, 0.6%) (0, 0.0%) (1, 1.0%)
(N = 116) (n = 19) (n = 97)
0.198 (29, 25.0%) (7, 36.8%) (22, 22.7%) 0.77
(16, 13.8%) (3, 15.8%) (13, 13.4%)
(17, 14.7%) (3, 15.8%) (14, 14.4%)
(54, 46.6%) (6, 31.6%) (48, 49.5%)
(N = 79) (n = 14) (n = 65)
0.113 (46, 58.2%) (9, 64.3%) (37, 56.9%) 0.575
(33, 41.8%) (5, 35.7%) (28, 43.1%)
(N = 97) (n = 15) (n = 82)
0.193 (61, 62.9%) (8, 53.3%) (53, 64.6%) 0.52
(36, 37.1%) (7, 46.7%) (29, 35.4%)
metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin
phic gastritis; IM, intestinal metaplasia.
.
Table 3 Reinfection and recrudescence rate of
Helicobacter pylori
Variable category E B M T group M E A group p-value*
Recrudescence (n = 60) (n = 120)
Yes 1 (1.7%) 4 (3.3%) 0.67
No 59 (98.3%) 116 (96.7%)
Reinfection (n = 59) (n = 116)
Yes 7 (11.9%) 19 (16.4%) 0.43
No 52 (88.1%) 97 (83.6%)
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d),
metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin
(400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.).
* P-value for Pearson chi-square test or Fisher’s exact test for comparison of
categorical data.
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istered orally; a second breath sample was collected
20 min later. The collected samples were analyzed using
an isotope-selective, non-dispersive infrared spectrom-
eter (UBiT-IR300; Otsuka Pharmaceutical). The cutoff
value used for H. pylori eradication was 2.5‰.
Follow-up of H. pylori tests
All of the eradicated patients received gastroscopy with
invasive tests (modified Giemsa stain and CLO test) not
only from greater and lesser curvature of antrum but
also from body after 1 year. If any one of these tests
were positive then the patient was regarded as recrudes-
cence case. After this time the patients were followed up
for one year with gastroscopy with invasive tests. How-
ever, when the patients preferred 13C-UBT or wanted to
receive the gastroscopy every other year it was also ac-







1≤ year <2 23 1.39
E 2≤ year <3 18 2.22
B 3≤ year <4 5 2.00
M 4≤ year <5 8 2.63
T 5≤ year <6 3 6.00
6≤ year <7 1 5.00
7≤ year <8 1 5.00
Total 59 2.05
1≤ year <2 39 1.36
M 2≤ year <3 37 2.05
E 3≤ year <4 30 3.67
A 4≤ year <5 10 3.80
Total 116 2.31
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d),
(400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.).insurance program recommends biannual endoscopy in-
stead of one year.
Statistical analysis
The annual reinfection rate (percentage per year) of H. pyl-
ori was calculated as (total number of infected patients/
cumulative observation years for all patients) X 100.
SPSS for Windows (version 18.0; SPSS, Inc., an IBM
Company, Chicago, Illinois, USA) was used for all statis-
tical analyses. Categorical variables were analyzed using
the Pearson chi-square test or Fisher’s exact test, and
continuous variables were analyzed using independent
samples t-test. The risk of H. pylori reinfection with time
was estimated using the Kaplan-Meier method. To de-
termine the risk factors for reinfection, we used the log-
rank test. Null hypotheses of no difference were rejected
if p-values were less than 0.05.
Results
Patient characteristics
Among eradicated 169 patients in the EBMT group and
eradicated 308 patients in the MEA group, 59 patients
and 116 patients maintained H. pylori-negative status
continuously for one year, respectively (Figure 1). Spe-
cifically, 110 patients dropped out in the EBMT group
and 192 in the MEA group for the following three rea-
sons: 97 patients in the EBMT group and 167 in the
MEA group for not returning for gastroscopy or 13C-
UBT after treatment, 12 in the EBMT group and 21 in
the MEA group for follow-up duration within 1 year, 1
patient in the EBMT group and 4 in the MEA group
for reappearance of H. pylori during 1 year follow-up.



















metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin
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The demographic and clinical characteristics of two study
groups, who maintained H. pylori-negative continuously
at one year after the EBMT or MEA therapy, are summa-
rized in Table 1. Gender, the mean age of the patients,
clinical diagnosis, atrophic gastritis, and intestinal meta-
plasia of the two groups were similar. The enrolled early
gastric cancer patients were cured by endoscopic sub-
mucosal dissection and follow-up was continuously
performed regularly. During long-term follow-up patients
in the EBMT or in the MEA group were divided into two
groups: reinfected group and continuously eradicated
group. The demographic and clinical characteristics of
the reinfected and continuously eradicated group are





Gender (N = 175) (n
Male (104, 59.4%) (16,
Female (71, 40.6%) (10,
Age (years) (mean ± SD) (N = 175) (n
(56.6 ± 9.4) (57.6
20-29 (2, 1.1%) (0,
30-39 (4, 2.3%) (0,
40-49 (34, 19.4%) (8, 3
50-59 (61, 34.9%) (6, 2
60-69 (62, 35.4%) (9, 3
70-79 (11, 6.3%) (3, 1
80-89 (1, 0.6%) (0,
Clinical diagnosis (N = 175) (n
Early gastric cancer (40, 22.9%) (7, 2
Dysplasia (19, 10.9%) (4, 1
Peptic ulcer disease (34, 19.4%) (7, 2
Chronic gastritis (82, 46.9%) (8, 3
Histological AG in either antrum
or body
(N = 116) (n
Yes (67, 57.8%) (14,
No (49, 42.2%) (6, 3
Histological IM in either antrum
or body
(N = 144) (n
Yes (84, 58.3%) (10,
No (60, 41.7%) (11,
Regimen (N = 175) (n
EBMT (59, 33.7%) (7, 2
MEA (116, 66.3%) (19,
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d),
(400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atro
All of early gastric cancer patients were cured by endoscopic submucosal dissection
* P-value for Log-rank test.MEA group, there was no significant evidence that re-
infection of H. pylori was related with gender, the mean
age of the patients, clinical diagnosis, atrophic gastritis,
and intestinal metaplasia. The H. pylori recrudescence
and reinfection rates are shown in Table 3. One patient
in the EBMT group and four patients in the MEA group,
who were H. pylori positive again at 1 year follow-up,
were assigned to recrudescence cases. The rate was cal-
culated at 1.7% (1/60) for the EBMT group and 3.3%
(4/120) for the MEA group, and these percentages were
not significantly different (p = 0.67). During long-term
follow-up 1 year after eradication H. pylori reappeared in 7
(11.9%) of EBMT group and in 19 (16.4%) of MEA group
and these percentages were not significantly different de-





= 26) (n = 149)
61.5%) (88, 59.1%) 0.75
38.5%) (61, 40.9%)
= 26) (n = 149)
± 9.4) (56.4 ± 9.5)







= 26) (n = 149)




= 20) (n = 96)
70.0%) (53, 55.2%) 0.14
0.0%) (43, 44.8%)
= 21) (n = 123)
47.6%) (74, 60.2%) 0.20
52.4%) (49, 39.8%)
= 26) (n = 149)
6.9%) (52, 34.9%) 0.23
73.1%) (97, 65.1%)
metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin
phic gastritis; IM, intestinal metaplasia.
.
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household.
Long-term follow-up and reinfection rate
The mean duration of follow-up of 59 patients in the
EBMT group and 116 in the MEA group was 31.9 months
(range: 18–90 months) and 30.4 months (range: 18–
59 months). The mean number of H. pylori tests per pa-
tient was found to be 2.05 tests for the EBMT group and
2.31 tests for the MEA group (Table 4). Reinfection with
H. pylori occurred in 7 of 59 patients of EBMT group
(11.9%) and in 19 of 116 patients of MEA group (16.4%)
sporadically during the follow-up period. The calcu-
lated total annual reinfection rate was found to be 4.45%
(7/157.17 patient years X 100) for EBMT and 6.46%
(19/294.08 patient years X 100) for MEA.
Risk factors for reinfection
When the reinfected group (n = 26) and continuously
eradicated group (n = 149) were compared in terms of
demographic information and clinical characteristics, no
statistical differences were found by univariate analysis
(Log-rank test), in both groups (Table 5). Specially, there
was no significant evidence that reinfection of H. pylori
is related with eradication regimen (p = 0.23) (Figure 2).
Discussion
We performed a prospective study to investigate reinfec-
tion rate of H. pylori in patients who had been successfully
treated with second-line therapy after an initial failure toFigure 2 Kaplan-Meier curves for Helicobacter pylori reinfection
according to regimen.eradicate H. pylori. To the best of our knowledge, this is
the first report comparing the reinfection rate of EBMT
and MEA therapy.
Reinfection is defined as an infection with a new strain
of H. pylori that is different from the original strain after
complete eradication, while recrudescence is a relapse of
original strain, which was temporarily suppressed by eradi-
cation therapy [14,15]. The recurrence rates of H. pylori
decrease with time and decline sharply after the first year,
and beyond the first year, recurrence rates come close to
the rate of natural acquisition of H. pylori infection in
adulthood [14,16,17]. From these reports the confirmation
of continuous H. pylori negativity for the first year after
eradication therapy has been accepted as complete eradi-
cation [18-20]. Therefore, in our study, reinfection was
defined as the situation where tests for H. pylori infec-
tion, after continuous H. pylori negativity for the first
year after eradication therapy, become positive again at a
later stage. In addition, patients, who become H. pylori
positive again during 1 year follow-up were classified as
recrudescence cases. We could not perfectly distinguish
between recrudescence of an original strain and reinfec-
tion because DNA analysis of the strain using molecular
fingerprinting techniques was not performed. However,
this definition is supported by data obtained using DNA
analysis that the cause of H. pylori recurrence after first
year is reinfection [14].
In the previous study, we reported that annual reinfec-
tion in patients received standard PPI-based triple eradi-
cation therapy in Korea was 3.51% and the recrudescence
rate 4.9% [11]. This result was similar to the mean annual
reinfection rate (3.4%), calculated from the studies per-
formed in developed countries [16]. The increase in anti-
microbial resistance with the standard triple therapy has
led to an increase of alternative therapy. However, there
are few reports regarding the reinfection of H. pylori in
patients received second-line therapy. In 2006, our group
reported the annual reinfection rate after second-line
therapy (EBMT) during 1996–2004, at 6.0% per patients-
years in Seoul, Korea [12]. In the present long-term
follow-up study for up to 90 months we investigated the
reinfection rate of EBMT and MEA therapy, performed
during 2003–2010 in Gyeonggi province near Seoul, and
those rates are 4.45% for EBMT and 6.46% for MEA per
year. When eradication has truly been successful, reinfec-
tion is associated with the risk of re-exposure to H. pylori.
Relatively low reinfection rates might be related to the
decrease in prevalence of H. pylori infection [21] and
the recent improvement of sanitation conditions in
Korea. In addition, when the reinfection rate of these
two kinds of rescue therapy were compared, there was
no significant difference (p = 0.43). Therefore, we suggest
that reinfection cannot affect the choice of second-line
treatment.
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and MEA group was found to be 1.7% and 3.3%, which
appears slightly lower than reported after initial eradi-
cation with standard PPI-based triple regimen (4.9%)
[11]. This result might be related to the decreasing
trend in eradication rate of standard triple therapy in
Korea. That is, the eradication rate of per protocol
(PP) analysis decreased up to 75.9% in 2006 [9]. Some
studies reported that the recurrence of H. pylori infec-
tion more frequently occurred in patients treated with
a low efficacy regimen than in those treated with a
high efficacy regimen, as a result of recrudescence of
the organism after temporary suppression, not elimin-
ation [14,16,22,23]. In the previous studies, the PP
eradication rates were reported at 77.2% for the 7- and
93.6% for the 14 day EBMT regimen [24], and 83.8%
for the 7-, 82.6% for the 10- and 79.9% for the 14 day
MEA regimen [25]. Our lower recrudescence rate
might be related to the higher efficacy of the EBMT
and MEA regimens. In addition, there was no differ-
ence in the recrudescence rate between EBMT and
MEA regimen (p = 0.67).
Limited information exists regarding risk factors for
reinfection of H. pylori. Candidate risk factors include
younger age [26,27], infection of close contacts [14,28],
dental plaque [29,30], and contaminated endoscopic equip-
ment [14,16,31]. Other studies did not identify any
factors predictive of H. pylori reinfection [32-34]. In
the previous study, we reported that male gender and
low income were significantly associated with reinfection
of H. pylori by multivariate analysis [11]. However, the
current study did not identify any predictive factors
concerning H. pylori reinfection in the EBMT group and
MEA group.
This study is the first study with large sample size and
a long-term follow-up period in the investigation of re-
infection rate of H. pylori in patients who had been suc-
cessfully treated with second-line therapy after an initial
failure to eradicate H. pylori. However, our study has
limitations. First, recrudescence cases could be included
in the reinfection cases. Theoretically the fingerprinting
should be performed for the differentiation of reinfected
and recrudescence. However, we did not perform DNA
analysis to identify the strains. In clinical practice, it is
not easy to perform DNA analysis. Secondly, despite our
efforts to enroll all patients, many patients dropped out
from this study, and refused to receive H. pylori tests
every year, especially when there was no gastrointestinal
symptom.
Conclusions
In summary, in Korea, the long-term reinfection rate
of H. pylori stayed low in both bismuth-containing
quadruple therapy and moxifloxacin-based triple therapy;thus reinfection cannot affect the choice of second-line
treatment.
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